Phase 1 × Terminated × Lymphoma, Mantle-Cell × Clear all
NCT05107856 2024-01-31

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

Prelude Therapeutics

Phase 1 Terminated
21 enrolled
NCT01769222 2024-01-24

Ipilimumab and Local Radiation for Selected Solid Tumors

Stanford University

Phase 1 Terminated
3 enrolled 5 charts
NCT01678443 2021-04-02

Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies

Fred Hutchinson Cancer Center

Phase 1 Terminated
2 enrolled 6 charts
NCT01643603 2020-12-17

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

Barbara Ann Karmanos Cancer Institute

Phase 1 Terminated
5 enrolled
NCT01609816 2020-03-16

Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma

Barbara Ann Karmanos Cancer Institute

Phase 1 Terminated
8 enrolled
NCT02168907 2018-07-02

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Wake Forest University Health Sciences

Phase 1 Terminated
1 enrolled
NCT00014560 2018-05-03

Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Dartmouth-Hitchcock Medical Center

Phase 1 Terminated
3 enrolled 3 charts
NCT00376519 2017-12-02

Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases

Masonic Cancer Center, University of Minnesota

Phase 1 Terminated
3 enrolled
NCT00005993 2017-11-29

Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer

Masonic Cancer Center, University of Minnesota

Phase 1 Terminated
NCT00725062 2017-11-29

Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Masonic Cancer Center, University of Minnesota

Phase 1 Terminated
3 enrolled
NCT00004239 2016-07-04

506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment

Alliance for Clinical Trials in Oncology

Phase 1 Terminated
10 enrolled
NCT01045928 2015-11-26

Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Case Comprehensive Cancer Center

Phase 1 Terminated
5 enrolled
NCT00671112 2015-10-28

Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

Case Comprehensive Cancer Center

Phase 1 Terminated
30 enrolled
NCT02109224 2015-08-20

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

National Cancer Institute (NCI)

Phase 1 Terminated
72 enrolled
NCT00800150 2015-06-08

Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment

City of Hope Medical Center

Phase 1 Terminated
6 enrolled
NCT00096005 2014-02-24

Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

National Cancer Institute (NCI)

Phase 1 Terminated
36 enrolled
NCT00176475 2013-09-17

Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease

Rutgers, The State University of New Jersey

Phase 1 Terminated
2 enrolled
NCT00996359 2013-09-17

Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation

Rutgers, The State University of New Jersey

Phase 1 Terminated
4 enrolled
NCT00103272 2013-06-04

17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

National Cancer Institute (NCI)

Phase 1 Terminated
74 enrolled
NCT00354185 2013-05-16

PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Terminated
36 enrolled
NCT00060112 2013-01-25

Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma

National Cancer Institute (NCI)

Phase 1 Terminated
15 enrolled